Current progress of CAR-T-cell therapy for patients with multiple myeloma
Authors:
- 23 May 2024
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (1) , 15-22
Abstract
Currently available chimeric antigen receptor (CAR)-engineered T-cell therapies targeting B-cell maturation antigen (BCMA), namely, idecabtagene vicleucel and ciltacabtagene autoleucel, have shown marked efficacy against relapsed and refractory multiple myeloma. However, further improvement in CAR-T-cell function is warranted as most patients treated with these products eventually relapse due to various mechanisms such as antigen loss and T-cell dysfunction or disappearance. Strategies for improving CAR-T-cell function include targeting of dual antigens, enhancing cell longevity through genetic modification, and eliminating the immunosuppressive tumor microenvironment. Serious side effects can also occur after CAR-T-cell infusions. Although understanding of the molecular pathogenesis of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome is growing, the unique movement disorder caused by BCMA-targeted therapy is less understood, and its molecular mechanisms must be further elucidated to establish better management strategies. In this article, we will review the current status of BCMA-targeting CAR-T-cell therapy. We will also highlight progress in the development of CAR-T cells targeting other antigens, as well as universal allogeneic CAR-T cells and bispecific antibodies.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP23H02779)
- Japan Agency for Medical Research and Development (JP22zf0127009, JP23ym0126072)
This publication has 60 references indexed in Scilit:
- γ-secretase directly sheds the survival receptor BCMA from plasma cellsNature Communications, 2015
- B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?Blood Cancer Journal, 2015
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Blood, 2014
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humansBlood, 2013
- Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survivalBritish Journal of Haematology, 2012
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004
- A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell GrowthJournal of Experimental Medicine, 2000
- In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.1995